首页> 美国卫生研究院文献>Journal of Clinical Microbiology >Field Evaluation of Dried Blood Spots for Routine HIV-1 Viral Load and Drug Resistance Monitoring in Patients Receiving Antiretroviral Therapy in Africa and Asia
【2h】

Field Evaluation of Dried Blood Spots for Routine HIV-1 Viral Load and Drug Resistance Monitoring in Patients Receiving Antiretroviral Therapy in Africa and Asia

机译:非洲和亚洲接受抗逆转录病毒治疗的患者常规HIV-1病毒载量干血斑现场评估和耐药性监测

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Dried blood spots (DBS) can be used in developing countries to alleviate the logistic constraints of using blood plasma specimens for viral load (VL) and HIV drug resistance (HIVDR) testing, but they should be assessed under field conditions. Between 2009 and 2011, we collected paired plasma-DBS samples from treatment-experienced HIV-1-infected adults in Burkina Faso, Cameroon, Senegal, Togo, Thailand, and Vietnam. The DBS were stored at an ambient temperature for 2 to 4 weeks and subsequently at −20°C before testing. VL testing was performed on the plasma samples and DBS using locally available methods: the Abbott m2000rt HIV-1 test, generic G2 real-time PCR, or the NucliSENS EasyQ version 1.2 test. In the case of virological failure (VF), i.e., a plasma VL of ≥1,000 copies/ml, HIVDR genotyping was performed on paired plasma-DBS samples. Overall, we compared 382 plasma-DBS sample pairs for DBS VL testing accuracy. The sensitivities of the different assays in different laboratories for detecting VF using DBS varied from 75% to 100% for the m2000rt test in labs B, C, and D, 91% to 93% for generic G2 real-time PCR in labs A and F, and 85% for the NucliSENS test in lab E. The specificities varied from 82% to 97% for the m2000rt and NucliSENS tests and reached only 60% for the generic G2 test. The NucliSENS test showed good agreement between plasma and DBS VL but underestimated the DBS VL. The lowest agreement was observed for the generic G2 test. Genotyping was successful for 96/124 (77%) DBS tested, and 75/96 (78%) plasma-DBS pairs had identical HIVDR mutations. Significant discrepancies in resistance interpretations were observed in 9 cases, 6 of which were from the same laboratory. DBS can be successfully used as an alternative to blood plasma samples for routine VL and HIVDR monitoring in African and Asian settings. However, the selection of an adequate VL measurement method and the definition of the VF threshold should be considered, and laboratory performance should be monitored.
机译:干血斑(DBS)可以在发展中国家使用,以减轻使用血浆样本进行病毒载量(VL)和HIV耐药性(HIVDR)测试时的后勤限制,但应在现场条件下进行评估。在2009年至2011年之间,我们从布基纳法索,喀麦隆,塞内加尔,多哥,泰国和越南的接受过治疗经历的HIV-1感染的成年人收集了成对的血浆DBS样本。在测试之前,将DBS在环境温度下保存2-4周,然后在-20°C下保存。 VL测试是使用当地可用的方法对血浆样品和DBS进行的:Abbott m2000rt HIV-1测试,通用G2实时PCR或NucliSENS EasyQ 1.2版测试。如果发生病毒学失败(VF),即血浆VL≥1,000拷贝/ ml,则对成对的血浆DBS样本进行HIVDR基因分型。总体而言,我们比较了382对血浆DBS样品对DBS VL测试的准确性。在实验室B,C和D中进行m2000rt测试,在不同实验室中使用DBS检测VF的不同检测方法的灵敏度在75%至100%之间,在实验室A和C中进行通用G2实时PCR的灵敏度在91%至93%之间。 F,实验室E中的NucliSENS测试为85%。m2000rt和NucliSENS测试的特异性从82%到97%不等,而通用G2测试的特异性仅为60%。 NucliSENS测试显示血浆与DBS VL之间具有良好的一致性,但低估了DBS VL。对于通用G2测试,观察到的最低要求。基因分型成功用于96/124(77%)的DBS测试,而75/96(78%)的血浆DBS对具有相同的HIVDR突变。在9例中观察到耐药性解释存在显着差异,其中6例来自同一实验室。在非洲和亚洲,DBS可以成功替代血浆样本,用于常规VL和HIVDR监测。但是,应考虑选择适当的VL测量方法和定义VF阈值,并应监测实验室性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号